Editors’ pickHealth

FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer

Presented in part at the Annual Meeting of the American Society of Clinical Oncology, Chicago, June 1–5, 2018.

PRODIGE (Partenariat de Recherche en Oncologie Digestive) 24 was supported by R&D Unicancer (which received a grant from Chugai Pharmaceutical), by a Clinical Research Hospital Program grant (PHRC11-006) from the French Ministry of Health and the Institut National du Cancer, and by the French National League against Cancer. The Canadian Cancer Trials Group Pancreatic Adenocarcinoma (CCTG PA.6) part of the trial was supported by a Program Grant (704970) from the Canadian Cancer Society and by grants from 7 Days in May.

Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.

Dr. Conroy reports receiving travel support from Roche; Dr. Hammel, receiving grant support, consulting fees, and travel support from Celgene; Dr. Ben Abdelghani, receiving fees for providing expert testimony and travel support from Amgen, Bayer, Merck, Sanofi, and Ipsen; Dr. Wei, receiving consulting fees from Celgene, Shire, Ethicon, and Ipsen and travel support from Bayer; Dr. Raoul, receiving fees for serving on an advisory board from Bayer, Bristol-Myers Squibb, BTG, Ipsen, AstraZeneca, and Terumo Medical; Dr. Francois, receiving consulting fees and travel support from Roche, Merck, and Servier and personal fees from Amgen, Sanofi, Lilly, Novartis, and Bayer; Dr. Ychou, receiving grant support, paid to his institution, and fees for serving as a board member from Bayer, Servier, and Amgen, and grant support, paid to his institution, from Roche; Dr. Di Fiore, receiving fees for a meeting presentation from Celgene; Dr. Bouhier-Leporrier, receiving consulting fees and travel support from Ipsen and Novartis, fees for serving on a speakers’ bureau from Amgen and MSD, and travel support from Bayer; Dr. Khemissa-Akouz, receiving personal fees from Sanofi and Ipsen and personal fees and travel support from Roche; Dr. Legoux, receiving consulting fees and travel support from Novartis, travel fees from Ipsen and Merck Serono, lecture fees and travel support from Servier, and grant support from Sanofi; Dr. Malka, receiving lecture fees and travel support from Amgen and Sanofi, lecture fees, consulting fees, and travel support from Bayer, Merck Serono, and Roche, consulting fees from Merck and Shire, and lecture fees and consulting fees from Servier and HalioDx; and Dr. Bachet, receiving consulting fees and lecture fees from Amgen, Bayer, Merck Serono, and Servier and lecture fees from Celgene, Roche, and Sanofi. No other potential conflict of interest relevant to this article was reported.

A data sharing statement provided by the authors is available with the full text of this article at NEJM.org.

We thank our patients and their families for their trust; the surgeons, supporting staff including pharmacists, Datacenter Unicancer members, Trevor Stanbury (R&D Unicancer), and research staff for monitoring data quality; the members of the PRODIGE intergroup (Unicancer Gastrointestinal, Fédération Francophone de Cancérologie Digestive, and Groupe Coopérateur Multidisciplinaire en Oncologie [GERCOR]) and the CCTG PA.6 group; the members of the independent data and safety monitoring committee (Bernard Asselain, M.D., Jean-Luc Van Laethem, M.D., and Antonio Sa Cunha, M.D.); the physicians and statisticians who helped to plan and realize this trial; the members of the quality-control team (Agnès Leroux, M.D., Jacques Thomas, M.D., Magali Fau, M.D., and Aurélien Lambert, M.D.); and Harriet Lamb, B.Sc., and Lee Miller, B.Sc., of Miller Medical Communications, for medical writing assistance with an earlier version of the manuscript.

Source link

Tags
Back to top button
close
Thanks !

Thanks for sharing this, you are awesome !

Pin It on Pinterest

Share This

Share this post with your friends!